Prediction of breast cancer and lymph node metastatic status with tumour markers using logistic regression models
- 18 February 2008
- journal article
- Published by Wiley in Journal of Evaluation in Clinical Practice
- Vol. 14 (2), 275-280
- https://doi.org/10.1111/j.1365-2753.2007.00849.x
Abstract
Aims Early detection of breast cancer can improve disease mortality. The aim of this study was to evaluate the effectiveness of serum biomarkers in the detection of primary breast cancer and lymph node metastatic status. Methods Serum samples were obtained from 55 female patients with breast cancer and 39 women without breast cancer. For these subjects, clinicopathological data were collected and serum levels of carcinoembryonic antigen, breast cancer‐specific cancer antigen 15.3 (CA15‐3), tissue polypeptide‐specific antigen (TPS), soluble interleukin‐2 receptor (sIL‐2R) and insulin‐like growth factor binding protein‐3 (IGFBP‐3) were assayed. Univariate and multivariate logistic regression were performed to evaluate the association between biomarkers and breast cancer, as well as lymph node metastatic status. Results For breast cancer prediction, the serum level of TPS had the best predictive value, with a sensitivity of 80% at an optimal cut‐off value of 69.1 U L−1. The combination of TPS, CA15‐3 and IGFBP‐3 with logistic regression model increased the sensitivity to 85%. For lymph node metastasis prediction, the serum level of sIL‐2R had the best predictive value, with a sensitivity of 66% at an optimal cut‐off value of 286 U mL−1. The combination of sIL‐2R and TPS with logistic regression model increased the sensitivity to 69%. Conclusion TPS may be useful in the detection of primary breast cancer, while sIL‐2R may be useful in lymph node metastasis prediction. The combination of more than one biomarker with logistic regression model can improve the predictive sensitivity.Keywords
This publication has 28 references indexed in Scilit:
- Tumour marker measurements in the diagnosis and monitoring of breast cancerCancer Treatment Reviews, 2000
- Circulating concentrations of insulin-like growth factor I and risk of breast cancerThe Lancet, 1998
- Breast Cancer in Singapore: Trends in Incidence 1968–1992International Journal of Epidemiology, 1996
- The Significance of Soluble lnterleukin-2, Soluble Interleuk in-2 Receptors, Soluble ICAM-1 and β2-Microglobulin in Breast Cancer PatientsTumor Biology, 1995
- TPS in Breast Cancer – A Comparative Study with Carcinoembryonic Antigen and CA 15-3Tumor Biology, 1992
- Prospective assessment of the role of five tumour markers in breast cancerCancer Immunology, Immunotherapy, 1991
- Serum soluble interleukin-2 (IL-2) receptor levels in women with breast carcinoma and its correlation with IL-2 receptor expression on blood lymphocytes and lymphocytic infiltration within the tumourCancer Immunology, Immunotherapy, 1991
- Assessment of four monoclonal antibodies as serum markers in breast cancerEuropean Journal of Cancer and Clinical Oncology, 1990
- T-cell markers in breast cancer patients at diagnosisClinical Immunology and Immunopathology, 1979